Journal article icon

Journal article

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status

Abstract:

Overexpression of HER2 is an important prognostic marker, and the only predictive biomarker of response to HER2-targeted therapies in invasive breast cancer. HER2- HER3 dimer has been shown to drive proliferation and tumor progression, and targeting of this dimer with pertuzumab alongside chemotherapy and trastuzumab, has shown significant clinical utility. The purpose of this study was to accurately quantify HER2-HER3 dimerisation in formalin fixed paraffin embedded (FFPE) breast cancer tiss...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.18632/oncotarget.9963

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Sub department:
CRUK/MRC Ox Inst for Radiation Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Sub department:
CRUK/MRC Ox Inst for Radiation Oncology
Role:
Author
Expand authors...
More from this funder
Grant:
C5255/A15935
C1519/A6906
King’s College London-UCL Comprehensive Cancer Imaging Centre More from this funder
More from this funder
Grant:
KCL Unit Funding KCL 06/07
Expand funders...
Publisher:
Impact Journals Publisher's website
Journal:
Oncotarget Journal website
Publication date:
2016-07-07
Acceptance date:
2016-05-23
DOI:
ISSN:
1949-2553
Source identifiers:
623824
Keywords:
Pubs id:
pubs:623824
UUID:
uuid:85852ba8-676c-4e8f-b167-6269689247bd
Local pid:
pubs:623824
Deposit date:
2016-05-25

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP